United States Biotechnology & Medical Research

ADC Therapeutics SA (ADCT)

Track

The most recent insider trading activity at ADC Therapeutics SA occurred on April 2, 2026. Redmile Group, LLC executed multiple sell transactions between March 31 and April 2, 2026, totaling several million shares. As these transactions occurred more than three months ago, no further context regarding current market performance is provided.
Ticker: ADCT Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for ADC Therapeutics SA. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 2 Apr 2026
Value US$4,261,715.48 | Price 108.83 | Shares 94,003 (+38.2%)
Sale 2 Apr 2026
Value US$2,897,369.09 | Price 394.53 | Shares 12,227 (-9.9%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-02 2026-04-02 S Sale
3.2
Redmile Group, LLC
Large shareholder
94,003 +38.2%
108.83
US$4,261,715 		94,003 +38.2% 108.83 US$4,261,715
2026-04-02 2026-04-02 S Sale
3.2
Redmile Group, LLC
Large shareholder
12,227 -9.9%
394.53
US$2,897,369 		12,227 -9.9% 394.53 US$2,897,369
2026-04-02 2026-04-01 S Sale
3.2
Redmile Group, LLC
Large shareholder
83,461 -8.1%
271.76
US$353,626 		83,461 -8.1% 271.76 US$353,626
2026-04-02 2026-04-01 S Sale
3.2
Redmile Group, LLC
Large shareholder
169,265 -1.1%
3.80
US$643,038 		169,265 -1.1% 3.80 US$643,038
2026-04-02 2026-03-31 S Sale
3.2
Redmile Group, LLC
Large shareholder
188,407 -1.4%
3.75
US$706,903 		188,407 -1.4% 3.75 US$706,903
2026-04-02 2026-03-31 S Sale
3.2
Redmile Group, LLC
Large shareholder
196,229 -1.3%
3.75
US$736,251 		196,229 -1.3% 3.75 US$736,251
2024-12-13 2024-12-11 B Purchase
3.2
Redmile Group, LLC
Large shareholder
50,000 +0.4%
3.81
US$190,500 		50,000 +0.4% 3.81 US$190,500
2024-12-13 2024-12-11 B Purchase
3.2
Redmile Group, LLC
Large shareholder
50,000 +0.4%
2.28
US$114,000 		50,000 +0.4% 2.28 US$114,000
2024-12-13 2024-12-11 B Purchase
3.2
Redmile Group, LLC
Large shareholder
50,000 +0.3%
3.81
US$190,500 		50,000 +0.3% 3.81 US$190,500
2024-12-13 2024-12-11 B Purchase
3.2
Redmile Group, LLC
Large shareholder
50,000 +0.3%
2.28
US$114,000 		50,000 +0.3% 2.28 US$114,000
2024-12-06 2024-12-04 S Sale
3.2
Redmile Group, LLC
Large shareholder
25,352 -0.2%
2.07
US$52,479 		25,352 -0.2% 2.07 US$52,479
2024-07-03 2024-07-01 B Purchase
3.2
Redmile Group, LLC
Large shareholder
400,000 +3.2%
2.81
US$1,124,000 		400,000 +3.2% 2.81 US$1,124,000
2024-07-03 2024-07-01 B Purchase
3.2
Redmile Group, LLC
Large shareholder
400,000 +2.6%
2.81
US$1,124,000 		400,000 +2.6% 2.81 US$1,124,000
2024-06-18 2024-06-17 PrS Proposed sale
0.8
Ron Squarer

Director

Non-Executive Director
6,995
2.89
US$20,216 		6,995 2.89 US$20,216
2024-06-18 2024-06-17 PrS Proposed sale
0.8
Robert Azelby

Director

Non-Executive Director
6,995
2.89
US$20,216 		6,995 2.89 US$20,216
2024-06-18 2024-06-17 PrS Proposed sale
0.8
Victor Sandor

Director

Non-Executive Director
6,995
2.89
US$20,216 		6,995 2.89 US$20,216
2024-06-18 2024-06-17 PrS Proposed sale
0.8
Jean Bizzari

Director

Non-Executive Director
6,995
2.89
US$20,216 		6,995 2.89 US$20,216
2024-06-18 2024-06-17 S Sale
0.8
Squarer Ron
Non-Executive Director
6,995 -8.0%
2.89
US$20,216 		6,995 -8.0% 2.89 US$20,216
2024-06-18 2024-06-17 S Sale
0.8
BIZZARI JEAN-PIERRE
Non-Executive Director
6,995 -8.1%
2.89
US$20,216 		6,995 -8.1% 2.89 US$20,216
2024-06-18 2024-06-17 S Sale
0.8
Pfisterer Thomas
Non-Executive Director
1,437 -0.7%
2.89
US$4,153 		1,437 -0.7% 2.89 US$4,153
2024-06-18 2024-06-17 S Sale
0.8
Sandor Victor
Non-Executive Director
6,995 -8.0%
2.89
US$20,216 		6,995 -8.0% 2.89 US$20,216
2024-06-18 2024-06-17 S Sale
0.8
Hug Peter
Non-Executive Director
1,193 -0.6%
2.89
US$3,448 		1,193 -0.6% 2.89 US$3,448
2024-06-18 2024-06-17 S Sale
2.5
Monges Viviane
Non-Executive Director
1,437 -1.3%
2.89
US$4,153 		1,437 -1.3% 2.89 US$4,153
2024-06-18 2024-06-17 S Sale
0.8
Azelby Robert
Non-Executive Director
6,995 -11.7%
2.89
US$20,216 		6,995 -11.7% 2.89 US$20,216
2024-05-09 2024-05-07 S Sale
3.3
MALLIK AMEET

Chief Executive Officer

Executive Director
29,731 -2.5%
4.48
US$133,195 		29,731 -2.5% 4.48 US$133,195
2024-05-07 2024-05-07 PrS Proposed sale
3.3
Ameet Mallik

Officer and Director

Executive Director
29,731
4.51
US$134,195 		29,731 4.51 US$134,195
Explore more

More insider trading research around ADC Therapeutics SA

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America